The National Cancer Institute's Laboratory of Tumor Immunology and Biology and Medical Oncology Branch, within the Center for Cancer Research, recently launched several new clinical trials. New clinical trials utilizing cancer vaccines relating to breast cancer are now being conducted at National Cancer Institute. For more information about National Cancer Institute's Clinical Trials visit their website at. www.cancer.gov/clincal_trials or phone 1-800-4-Cancer (1-800-422-6237) to speak with NCI Cancer Information Specialists to help you find a clinical trial or answer any questions you may have about cancer.

For more information about the vaccines used in the trials, go to: http://ccr.cancer.gov/Labs/Lab.asp?LabID=39

For additional cancer information, call the Cancer Information Service: 1-800-422-6237

A Phase III clinical trial (last phase prior to FDA review) evaluating the investigative chemotherapy agent Myocet (liposomal encapsulated doxorubicin) in addition to standard therapy for HER2-positive breast cancer is now enrolling patients.

Researchers are now enrolling patients with metastatic, HER2-positive breast cancer to further evaluate the effectiveness of Myocet. This trial will be directly comparing a standard treatment option consisting of trastuzumab plus paclitaxel to the combination of Myocet plus trazumab and paclitaxel as initial therapy for metastatic breast cancer. The goal of the trial is to determine if the addition of Myocet to standard therapy can improve anticancer responses among these patients.

For more information on enrollment in this trial, click here